CO6150139A2 - Sal de tartrato de 1-[2- fluoruro-4-(trifluorometil)fenil]-3-(3-{[4-metil-5-(4-metil-1,3 oxazol-5-il)-4h-1,2,4-triazol-3 il]tio}propil)-3-azabiciclo[3.1.0]-hexano y a sus solvatos, formulaciones farmaceuticas, procedimientos para su preparacion y su - Google Patents
Sal de tartrato de 1-[2- fluoruro-4-(trifluorometil)fenil]-3-(3-{[4-metil-5-(4-metil-1,3 oxazol-5-il)-4h-1,2,4-triazol-3 il]tio}propil)-3-azabiciclo[3.1.0]-hexano y a sus solvatos, formulaciones farmaceuticas, procedimientos para su preparacion y suInfo
- Publication number
- CO6150139A2 CO6150139A2 CO09017330A CO09017330A CO6150139A2 CO 6150139 A2 CO6150139 A2 CO 6150139A2 CO 09017330 A CO09017330 A CO 09017330A CO 09017330 A CO09017330 A CO 09017330A CO 6150139 A2 CO6150139 A2 CO 6150139A2
- Authority
- CO
- Colombia
- Prior art keywords
- methyl
- oxazol
- triazol
- phenyl
- azabiciclo
- Prior art date
Links
- 239000012453 solvate Substances 0.000 title abstract 4
- CIUQDSCDWFSTQR-UHFFFAOYSA-N [C]1=CC=CC=C1 Chemical compound [C]1=CC=CC=C1 CIUQDSCDWFSTQR-UHFFFAOYSA-N 0.000 title 1
- 238000000034 method Methods 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- 150000003892 tartrate salts Chemical class 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 5
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 3
- 229940095064 tartrate Drugs 0.000 abstract 3
- PUMREIFKTMLCAF-UHFFFAOYSA-N 4-methyl-1,3-oxazole Chemical compound CC1=COC=N1 PUMREIFKTMLCAF-UHFFFAOYSA-N 0.000 abstract 2
- ZKRWPAYTJMRKLJ-BTYIYWSLSA-N 5-[5-[3-[(1s,5r)-1-[2-fluoro-4-(trifluoromethyl)phenyl]-3-azabicyclo[3.1.0]hexan-3-yl]propylsulfanyl]-4-methyl-1,2,4-triazol-3-yl]-4-methyl-1,3-oxazole Chemical compound N1=COC(C=2N(C(SCCCN3C[C@]4(C[C@H]4C3)C=3C(=CC(=CC=3)C(F)(F)F)F)=NN=2)C)=C1C ZKRWPAYTJMRKLJ-BTYIYWSLSA-N 0.000 abstract 2
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 abstract 2
- 125000000446 sulfanediyl group Chemical group *S* 0.000 abstract 2
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 abstract 2
- -1 {[4-methyl-5- (4-methyl-1,3-oxazol-5-yl) -4H- 1,2,4-triazol-3-yl] thio} propyl Chemical group 0.000 abstract 2
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 abstract 1
- 235000002906 tartaric acid Nutrition 0.000 abstract 1
- 239000011975 tartaric acid Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/34—Tobacco-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Addiction (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Psychology (AREA)
- Pain & Pain Management (AREA)
- Anesthesiology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Diabetes (AREA)
- Child & Adolescent Psychology (AREA)
- Otolaryngology (AREA)
- Gynecology & Obstetrics (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/EP2006/008314 WO2007022980A1 (en) | 2005-08-22 | 2006-08-21 | Use of azabicyclo hexane derivatives |
| GBGB0616574.0A GB0616574D0 (en) | 2006-08-21 | 2006-08-21 | Compounds |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CO6150139A2 true CO6150139A2 (es) | 2010-04-20 |
Family
ID=37081324
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CO09017330A CO6150139A2 (es) | 2006-08-21 | 2009-02-20 | Sal de tartrato de 1-[2- fluoruro-4-(trifluorometil)fenil]-3-(3-{[4-metil-5-(4-metil-1,3 oxazol-5-il)-4h-1,2,4-triazol-3 il]tio}propil)-3-azabiciclo[3.1.0]-hexano y a sus solvatos, formulaciones farmaceuticas, procedimientos para su preparacion y su |
Country Status (22)
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR101143718B1 (ko) * | 2004-02-23 | 2012-07-05 | 글락소 그룹 리미티드 | 도파민 ｄ3 수용체의 조절제로서 유용한 아자비시클로(3.1.0) 헥산 유도체 |
| GB0507602D0 (en) * | 2005-04-14 | 2005-05-18 | Glaxo Group Ltd | Compounds |
| GB0507601D0 (en) * | 2005-04-14 | 2005-05-18 | Glaxo Group Ltd | Compounds |
| GB0512099D0 (en) * | 2005-06-14 | 2005-07-20 | Glaxo Group Ltd | Compounds |
| JP5068747B2 (ja) * | 2005-06-14 | 2012-11-07 | グラクソ グループ リミテッド | ドーパミンｄ３受容体のモジュレーターとしてのアザビシクロ［３．１．０］ヘキサン誘導体 |
| GB0517187D0 (en) * | 2005-08-22 | 2005-09-28 | Glaxo Group Ltd | Compounds |
| ATE487715T1 (de) * | 2005-08-22 | 2010-11-15 | Glaxo Group Ltd | Triazolderivate als modulatoren von dopamin-d3- rezeptoren |
| GB0517191D0 (en) | 2005-08-22 | 2005-09-28 | Glaxo Group Ltd | Compounds |
| GB0517175D0 (en) | 2005-08-22 | 2005-09-28 | Glaxo Group Ltd | Compounds |
| GB0517193D0 (en) * | 2005-08-22 | 2005-09-28 | Glaxo Group Ltd | Novel use |
| WO2007113260A1 (en) * | 2006-04-03 | 2007-10-11 | Glaxo Group Limited | Azabicyclo [3. 1. o] hexyl derivatives as modulators of dopamine d3 receptors |
| EP2010518B1 (en) * | 2006-04-03 | 2011-02-16 | Glaxo Group Limited | Azabicyclo [3. 1. o] hexane derivatives as modulators of dopamine d3 receptors |
| WO2008153937A2 (en) * | 2007-06-06 | 2008-12-18 | Dov Pharmaceutical, Inc. | Novel 1- heteroaryl-3-azabicyclo[3.1.0]hexanes, methods for their preparation and their use as medicaments |
| US9133159B2 (en) | 2007-06-06 | 2015-09-15 | Neurovance, Inc. | 1-heteroaryl-3-azabicyclo[3.1.0]hexanes, methods for their preparation and their use as medicaments |
| WO2019146740A1 (ja) | 2018-01-26 | 2019-08-01 | 塩野義製薬株式会社 | ドーパミンｄ３受容体拮抗作用を有する環式化合物 |
| US12115154B2 (en) | 2020-12-16 | 2024-10-15 | Srx Cardio, Llc | Compounds for the modulation of proprotein convertase subtilisin/kexin type 9 (PCSK9) |
| AR127055A1 (es) | 2021-09-14 | 2023-12-13 | Lilly Co Eli | Sales agonistas de sstr4 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP4260941B2 (ja) * | 1998-11-09 | 2009-04-30 | 株式会社片山製薬所 | アゼチジン−３−オール |
| EP1163217B1 (en) * | 1999-03-15 | 2005-09-21 | Novo Nordisk A/S | New salt of (2r,3r,4r)-3,4-dihydroxy-2-hydroxymethylpyrrolidine |
| GB0019228D0 (en) * | 2000-08-04 | 2000-09-27 | Smithkline Beecham Plc | Novel pharmaceutical |
| KR101143718B1 (ko) * | 2004-02-23 | 2012-07-05 | 글락소 그룹 리미티드 | 도파민 ｄ3 수용체의 조절제로서 유용한 아자비시클로(3.1.0) 헥산 유도체 |
| SE526837C2 (sv) * | 2004-02-24 | 2005-11-08 | Kongsberg Automotive Asa | Växelspakstransmission |
| AU2005267579A1 (en) * | 2004-06-30 | 2006-02-02 | Eli Lilly And Company | 1 (indole-6-carbonyl-D-phenylglycinyl) -4- (1-methylpiperidin-4-yl) piperazine D-tartrate |
| GB0517193D0 (en) * | 2005-08-22 | 2005-09-28 | Glaxo Group Ltd | Novel use |
-
2006
- 2006-08-21 GB GBGB0616574.0A patent/GB0616574D0/en not_active Ceased
-
2007
- 2007-08-17 PE PE2007001117A patent/PE20080609A1/es not_active Application Discontinuation
- 2007-08-20 WO PCT/EP2007/058636 patent/WO2008022994A1/en not_active Ceased
- 2007-08-20 CA CA002661437A patent/CA2661437A1/en not_active Abandoned
- 2007-08-20 TW TW096130644A patent/TW200825074A/zh unknown
- 2007-08-20 CN CN2007800392082A patent/CN101528221B/zh not_active Expired - Fee Related
- 2007-08-20 BR BRPI0716454-8A2A patent/BRPI0716454A2/pt not_active IP Right Cessation
- 2007-08-20 KR KR1020097003484A patent/KR101495362B1/ko not_active Expired - Fee Related
- 2007-08-20 EA EA200970211A patent/EA017917B1/ru not_active IP Right Cessation
- 2007-08-20 AU AU2007287527A patent/AU2007287527B2/en not_active Ceased
- 2007-08-20 US US11/841,015 patent/US20080058398A1/en not_active Abandoned
- 2007-08-20 JP JP2009525046A patent/JP5315244B2/ja not_active Expired - Fee Related
- 2007-08-20 MX MX2009001941A patent/MX2009001941A/es active IP Right Grant
- 2007-08-20 CL CL200702422A patent/CL2007002422A1/es unknown
- 2007-08-20 EP EP07788490A patent/EP2054054A1/en not_active Withdrawn
- 2007-08-21 AR ARP070103715A patent/AR062471A1/es not_active Application Discontinuation
-
2009
- 2009-02-06 ZA ZA2009/00886A patent/ZA200900886B/en unknown
- 2009-02-09 IL IL196976A patent/IL196976A0/en unknown
- 2009-02-20 CO CO09017330A patent/CO6150139A2/es unknown
- 2009-02-23 NO NO20090834A patent/NO20090834L/no not_active Application Discontinuation
- 2009-02-25 CR CR10638A patent/CR10638A/es not_active Application Discontinuation
- 2009-02-27 MA MA31673A patent/MA30672B1/fr unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EA200970211A1 (ru) | 2009-08-28 |
| AU2007287527A1 (en) | 2008-02-28 |
| MX2009001941A (es) | 2009-03-05 |
| KR101495362B1 (ko) | 2015-02-24 |
| GB0616574D0 (en) | 2006-09-27 |
| TW200825074A (en) | 2008-06-16 |
| AR062471A1 (es) | 2008-11-12 |
| BRPI0716454A2 (pt) | 2014-03-04 |
| ZA200900886B (en) | 2011-05-25 |
| NO20090834L (no) | 2009-03-19 |
| WO2008022994A1 (en) | 2008-02-28 |
| US20080058398A1 (en) | 2008-03-06 |
| EA017917B1 (ru) | 2013-04-30 |
| CN101528221A (zh) | 2009-09-09 |
| CA2661437A1 (en) | 2008-02-28 |
| MA30672B1 (fr) | 2009-08-03 |
| AU2007287527B2 (en) | 2013-01-31 |
| EP2054054A1 (en) | 2009-05-06 |
| CR10638A (es) | 2009-03-20 |
| CN101528221B (zh) | 2013-05-08 |
| CL2007002422A1 (es) | 2008-03-14 |
| PE20080609A1 (es) | 2008-07-26 |
| IL196976A0 (en) | 2009-11-18 |
| JP5315244B2 (ja) | 2013-10-16 |
| KR20090052327A (ko) | 2009-05-25 |
| JP2010501519A (ja) | 2010-01-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CO6150139A2 (es) | Sal de tartrato de 1-[2- fluoruro-4-(trifluorometil)fenil]-3-(3-{[4-metil-5-(4-metil-1,3 oxazol-5-il)-4h-1,2,4-triazol-3 il]tio}propil)-3-azabiciclo[3.1.0]-hexano y a sus solvatos, formulaciones farmaceuticas, procedimientos para su preparacion y su | |
| RU2378259C2 (ru) | Новые производные аминоиндазолов в качестве лекарственных средств и содержащие их фармацевтические композиции | |
| ES2651843T3 (es) | Derivados de pirazolopirrolidina y su uso en el tratamiento de enfermedades | |
| PE20120626A1 (es) | Composiciones farmaceuticas que comprende nilotinib | |
| ES2536191T3 (es) | Derivados de sulfonamida | |
| RU2223116C2 (ru) | Применение производных арил (или гетероарил) азолилкарбинолов в приготовлении лекарственного средства для лечения нарушений, опосредованных избытком вещества p | |
| EA201000486A1 (ru) | Ингибитор белка, активирующего 5-липоксигеназу (flap) | |
| NO20084659L (no) | Ko-krystall av C-glucosidderivat og L-prolin | |
| JP2010513319A5 (cg-RX-API-DMAC7.html) | ||
| UA112055C2 (uk) | Солі 4-[2-[[5-метил-1-(2-нафталініл)-1h-піразол-3-іл]оксі]етил]морфоліну | |
| CO6231025A2 (es) | Sal de napadisilato de 5-(2-{[6-(2,2-difluoro-2-feniletoxi)hexil]amino}-1hidroxietil)-8-hidroxiquinolin-2(1h)-ona como agonista del receptor adrenergico beta2 | |
| MA34207B1 (fr) | Inhibiteurs de la pi3 kinase et/ou du mtor | |
| NZ591427A (en) | P38 map kinase inhibitors | |
| RU2013107007A (ru) | Бифункциональные соединения, являющиеся ингибиторами rho-киназы, композиция и применение | |
| RU2013130222A (ru) | Применение сигма-лигандов от боли при раке костей | |
| RU2017121370A (ru) | Противогрибковые агенты | |
| HUE029485T2 (en) | New cyclohexylamine derivatives with B2 adrenergic agonist and M3 muscarinic antagonist activity | |
| AU2016380349A1 (en) | Metalloenzyme inhibitor compounds | |
| JP2014501732A5 (cg-RX-API-DMAC7.html) | ||
| PH12012501510A1 (en) | 4-[-2-[[5-methyl-1-(2-naphtalenyl)-1h-pyrazol-3-yl]oxy]ethyl]morpholine hydrochloride polymorphs and solvates | |
| MX2010004176A (es) | Derivado de triazol 1,3,5-trisustituido. | |
| SI2855449T1 (en) | SULFONYL PIPERIDIN DERIVATIVES AND THEIR USE IN TREATMENT OF PROKINETICINAL DISEASE DISEASES | |
| RU2008120850A (ru) | Соединения и композиции в качестве ингибиторов протеинкиназ | |
| HRP20080446T3 (en) | Monohydrochloride salt of 1-[3-[3-(4-chlorophenyl)propoxy]propyl]-piperidine | |
| AR069743A1 (es) | Derivados de pirazol como inhibidores de 5-lipoxigenasa |